Arizona State Retirement System Cuts Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Arizona State Retirement System lessened its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 15.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,812 shares of the biopharmaceutical company’s stock after selling 2,177 shares during the quarter. Arizona State Retirement System’s holdings in Theravance Biopharma were worth $133,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in Theravance Biopharma by 324.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 4,402 shares during the last quarter. Newtyn Management LLC lifted its position in shares of Theravance Biopharma by 12.3% during the 3rd quarter. Newtyn Management LLC now owns 1,841,560 shares of the biopharmaceutical company’s stock worth $15,893,000 after purchasing an additional 201,104 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Theravance Biopharma by 4.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 44,532 shares of the biopharmaceutical company’s stock worth $384,000 after purchasing an additional 1,993 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Theravance Biopharma by 67.1% during the third quarter. SG Americas Securities LLC now owns 252,609 shares of the biopharmaceutical company’s stock worth $2,180,000 after purchasing an additional 101,475 shares in the last quarter. Finally, GSA Capital Partners LLP increased its holdings in Theravance Biopharma by 1,536.4% in the third quarter. GSA Capital Partners LLP now owns 325,985 shares of the biopharmaceutical company’s stock valued at $2,813,000 after buying an additional 306,064 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Price Performance

Shares of TBPH opened at $9.46 on Tuesday. Theravance Biopharma, Inc. has a 1-year low of $8.21 and a 1-year high of $11.98. The stock has a market cap of $459.38 million, a PE ratio of -9.75 and a beta of 0.36. The firm has a fifty day moving average price of $9.03 and a 200 day moving average price of $9.68.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $17.57 million for the quarter, compared to analyst estimates of $17.49 million. Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. As a group, equities analysts expect that Theravance Biopharma, Inc. will post -0.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on TBPH. Evercore ISI cut Theravance Biopharma from an “outperform” rating to an “inline” rating in a research report on Monday, January 8th. BTIG Research assumed coverage on Theravance Biopharma in a report on Friday, April 12th. They issued a “buy” rating and a $21.00 price target for the company.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.